Lundbeck Pins Hopes On New Product Launches, Ex-Europe Growth To Reverse Revenue Drain

Denmark's CNS drugs specialist Lundbeck expects three 2013 product launches, a portfolio of new medicines and a marketing drive into markets outside anemic Europe to help offset lost revenue and profits caused by escitalopram patent expiry in the U.S. and Europe.